Q515 - Notice of Intent to Sole-Source Requirement: Artera AI Prostate Exam Testing - Cleveland VAMC

information, such as age, tumor stage, and lab results; Predictive Modeling: The AI algorithm predicts which patients are likely to benefit from specific therapies, such as short-term androgen deprivation therapy (ST-ADT) in prostate cancer; Outcome Estimation: It estimates long-term outcomes, including disease progression and metastasis risk, helping clinicians tailor treatment plans Artera AI Prostate is the first MMAI test recommended in the NCCN Clinical Practice Guidelines for prostate cancer. It identifies patients who may benefit most from hormone therapy and supports early-stage treatment decisions. Benefits of this testing are early intervention providing actionable insights to guide therapy selection and improve patient outcomes for our prostate cancer patients. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet this requirement. It is the Government's intention to solicit and negotiate with only this source. This notice of intent is not a request for competitive proposals. IAW FAR 5.207 all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. This is not a solicitation or request for offers. No solicitation package is available. Any response to this notice must show clear and convincing evidence that demonstrates the ability to comply with the requirement and that competition would be advantageous to the Government. The Government will not pay for information submitted. A determination not to compete based on responses to this notice is solely within the discretion of the Government. All responses to this intent to sole source must be emailed to Thomas Bellamy: [email protected] and Samantha Jarrett: [email protected] by 3:00 p.m. EST November 10th, 2026.